Intellia Therapeutics (NTLA) is back in focus after releasing detailed Phase 3 HAELO trial data for its CRISPR-based therapy lonvo-z in hereditary angioedema, alongside a rolling biologics license application with the FDA.

The latest HAELO data and rolling BLA have coincided with a sharp shift in sentiment toward Intellia Therapeutics, with a 7 day share price return of 29.40% and a year to date share price return of 70.14%, set against a 3 year total shareholder return that is down 61.76%.

If Intellia’s progress in gene editing has caught your attention, this can be a useful moment to broaden your watchlist with other healthcare focused AI opportunities via the 41 healthcare AI stocks.

With Intellia Therapeutics shares up 70.14% year to date yet still trading well below their 3 year peak, and with analysts’ targets sitting above the current US$15.67 price, are you seeing a fresh entry point or a market already pricing in future growth?

Most Popular Narrative: 41.2% Undervalued

On the most followed narrative, Intellia Therapeutics screens as undervalued, with a fair value of $26.63 versus the recent $15.67 close, hinging on ambitious growth and profitability assumptions.

Improving financial discipline, as evidenced by successful restructuring, declining GAAP operating expenses (~10% reduction YoY), and a robust cash runway into the first half of 2027, enables Intellia to absorb increased R&D investment, advance pipeline expansion, and build out commercial infrastructure without dilutive fundraising. This supports protection of net margins and improves future earnings visibility.

Want to see what sits behind that confidence in Intellia Therapeutics, from revenue acceleration assumptions to a future profit margin swing and a premium earnings multiple narrative?

Result: Fair Value of $26.63 (UNDERVALUED)

However, Intellia Therapeutics still faces key risks, including future funding needs given ongoing losses of $394.6 million and heavy reliance on a small number of lead programs.

Another View on Intellia Therapeutics Valuation

The analyst narrative frames Intellia Therapeutics as undervalued versus a fair value of $26.63, yet the current P/S of 33.1x looks demanding next to both the US Biotechs industry at 10.8x and peers at 29.9x, and far above a fair ratio of 0.1x. This raises the question of how much optimism is already in the price.

To see how these P/S gaps could matter for your risk and return expectations over time, it is worth looking more closely at the valuation work behind them. This includes how that fair ratio is derived and what might push the market toward it, in our valuation breakdown, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on Intellia Therapeutics split between potential and caution, this is a useful moment to move quickly, review the numbers and form your own stance. To weigh those concerns against the upside that some investors see, start by checking the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Intellia Therapeutics?

If Intellia Therapeutics has sharpened your focus on where you commit capital, do not stop here. Broaden your horizons and test fresh ideas with targeted screeners.

• Target potential mispricing by scanning companies that combine quality fundamentals with attractive valuations through the 45 high quality undervalued stocks.
• Prioritize resilience by filtering for businesses with strong finances using the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for underfollowed potential by reviewing the screener containing 20 high quality undiscovered gems before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.